SCHEDULE: Avidity Partners Maintains 9.9% Stake in Context Therapeutics

Avidity Partners Management LP and related entities reported a 9.9% beneficial ownership stake in Context Therapeutics Inc. as of September 30, 2025.

Summary

• Avidity Partners Management LP, along with its general partner Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, and Michael Gregory, collectively beneficially own 9,200,580 shares of Context Therapeutics Inc. Common Stock.
• This aggregate ownership represents 9.9% of the class of securities.
• Avidity Master Fund LP beneficially owns 4,510,100 shares, representing 4.9% of the class.
• Avidity Private Master Fund I LP beneficially owns 7,776,296 shares, representing 8.2% of the class.
• All reporting persons, including Michael Gregory, have shared voting and shared dispositive power over their respective reported shares.
• The securities were not acquired or held for the purpose of changing or influencing control of Context Therapeutics Inc., other than activities solely in connection with a nomination under Rule 14a-11.
• All reported securities are directly owned by advisory clients of Avidity Partners Management LP, with only Avidity Private Master Fund I LP beneficially owning more than 5% of the Common Stock among these clients.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment towards the company, indicating a neutral impact.

Positives

• A significant institutional investor group, Avidity Partners, continues to hold a substantial 9.9% stake in Context Therapeutics Inc., indicating continued investment interest.

Risks

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, which mitigates immediate activist investor risk, but the possibility of future nominations under Rule 14a-11 is noted.

Future Outlook

NA

Management Comments

• Michael Gregory, Managing Member of Avidity Partners Management (GP) LLC, certified that to the best of his knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor group in a publicly traded biotechnology or pharmaceutical company, common in the sector for transparency regarding significant stakes.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake and their passive investment intent, which can offer a degree of stability or confidence.

Key Dates

Keywords

Context Therapeutics Inc., Avidity Partners, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Equity Stake